Adlai Nortye (ANL) Stock Price, News & Analysis

Company Overview

Adlai Nortye Inc. (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control. Adlai Nortye’s global marketing and distribution network extends across Asia, Europe, North America and other regions, enabling the company to tailor products to diverse regulatory requirements and performance standards worldwide.

Since its founding in the mid-2000s, Adlai Nortye has pursued capacity expansions, new product development and strategic partnerships to strengthen its position in the fine chemicals sector. The leadership team, comprised of professionals with expertise in chemistry, engineering and international business, continues to advance initiatives designed to improve production efficiency, expand the product portfolio and enhance the company’s global market presence.

Key Stats

• Today's Range: $10.50 to $12.15
• 50-Day Range: $6.46 to $16.60
• 52-Week Range: $0.88 to $17.25
• Volume: 221,977 shs
• Average Volume: 555,035 shs
• Market Capitalization: $462.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.67
• Consensus Rating: Moderate Buy

Adlai Nortye Stock Analysis - MarketRank™

Adlai Nortye scored higher than 42% of companies evaluated by MarketBeat, and ranked 642nd out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adlai Nortye has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Adlai Nortye has a consensus price target of $21.67, representing about 89.3% upside from its current price of $11.45.

Amount of Analyst Coverage

Adlai Nortye has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adlai Nortye are expected to decrease in the coming year, from ($0.20) to ($0.26) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.35% of the float of Adlai Nortye has been sold short.

Short Interest Ratio / Days to Cover

Adlai Nortye has a short interest ratio ("days to cover") of 4.36.

Change versus previous month

Short interest in Adlai Nortye has recently increased by 28.16%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adlai Nortye does not currently pay a dividend.

Dividend Growth

Adlai Nortye does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.33

News Sentiment

Adlai Nortye has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Adlai Nortye this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for ANL on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

1 people have added Adlai Nortye to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Adlai Nortye insiders have not sold or bought any company stock.

Percentage Held by Institutions

35.21% of the stock of Adlai Nortye is held by institutions.

Company Calendar

• Today: 5/20/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANL
• Previous Symbol: NASDAQ:ANL
• CIK: 1944552
• Web: www.adlainortye.com
• Phone: 848-230-7430
• Fax: N/A
• Employees: 127
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Adlai Nortye: $21.67
• High Price Target: $23.00
• Low Price Target: $20.00
• Potential Upside/Downside: +87.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.65
• Quick Ratio: 0.65

Sales & Book Value

• Annual Sales: $5 million
• Price / Sales: 92.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.21) per share
• Price / Book: -55.07

Miscellaneous

• Outstanding Shares: 40,000,000
• Free Float: N/A
• Market Cap: $462.60 million
• Optionable: Not Optionable
• Beta: 1.23